Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This first-in-human open-label, multi center, dose-escalation and expansion study is designed
to evaluate the safety, tolerability, and PK of BAT6021 alone or in combination with BAT1308
(an anti-PD-1 antibody) in participants with locally advanced, recurrent, or metastatic
incurable tumors for whom standard therapy does not exist, has proven to be ineffective or
intolerable, or is considered inappropriate, or for whom a clinical trial of an
investigational agent is a recognized standard of care.